Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Screening assays identify TMPRSS2 inhibitors from drug repurposing candidates useful as COVID-19 therapeutic

Researchers used an assay toolset for discovering new transmembrane protease serine 2 inhibiting drug repurposing candidates, that can be useful as therapeutics for COVID-19 treatment.

10 Feb 2022

Omicron resists antibodies, causes less severe disease than previous SARS-CoV-2variants

In two recent studies, researchers at Washington University School of Medicine in St. Louis found evidence that the omicron variant of the virus that causes COVID-19 causes less severe disease than previous variants — at least in rodents — but that many antibody-based therapies may not be effective against it.

10 Feb 2022

Study examines whether viagra-like drug may be effective in treating vascular dementia

A new study, published today in Alzheimer's & Dementia, tested whether tadalafil, a drug closely related to Viagra, may be effective in treating people with vascular dementia.

9 Feb 2022

Research reveals why Black women experience higher breast cancer mortality

New research from Sanford Burnham Prebys has revealed significant molecular differences between the breast cells of white and Black women that help explain why Black women experience higher breast cancer mortality.

9 Feb 2022

Researchers identify a bivalent histone-mark switch essential for angiogenesis

Defying conventional epigenomic wisdom, the non-conventional polycomb (PRC)1 variant paradoxically overwhelms the conventional PRC-mediated gene silencing in activated endothelial cells.

8 Feb 2022

Using interdisciplinary approach to beat cancer

European Cooperation in Science and Technology (COST) World Cancer Day aims at raising awareness of cancer and to encourage its prevention, detection, and treatment.

4 Feb 2022

Study provides atomistic level insight into target residence time of small molecule kinase inhibitors

When a drug molecule binds to its target protein, it stays bound for some time before eventually unbinding the target. The actual time how long a drug molecule resides bound to its target varies among compounds.

29 Jan 2022

New study offers valuable information on ocular drug metabolism and pharmacokinetics

Severe visual illnesses are increasing in our society, and effective treatments are missing for diseases as age-related macular degeneration, diabetic retinopathy, and glaucoma. Both industry and academia are highly interested to advance ocular drug discovery and development.

29 Jan 2022

Blood proteoforms may help predict liver transplant rejection

Northwestern University scientists have discovered families of proteins in the body that could potentially predict which patients may reject a new organ transplant, helping inform decisions about care.

27 Jan 2022

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Researchers show that the CHI3L1 inhibitors reduce epithelial cell infection by SARS-CoV-2 VOC pseudovirus moieties.

27 Jan 2022

AMSBIO Expands EU Operations

...

From AMS Biotechnology 26 Jan 2022

Study opens the door to a new approach to attacking herpesviruses

A new study published this week in mBio, an open access journal of the American Society for Microbiology, has opened the door to a new approach to attacking herpesviruses.

25 Jan 2022

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

In a recent study posted to the bioRxiv* preprint server, researchers developed a novel bioinformatic algorithm to predict host cleavage targets of the SARS-CoV-2 3C-like protease (3CLPro).

23 Jan 2022

CENTOGENE teams up with Insilico Medicine to improve therapeutic targets for Niemann-Pick disease type C

A commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI) - driven drug discovery company, today announced a research and development collaboration to accelerate the discovery of novel therapeutic targets for Niemann-Pick disease type C

21 Jan 2022

New cryo-EM method may be able to shortcut a big step in modern vaccine development

Scientists at Scripps Research have devised a method that may be able to shortcut one of the big steps in modern vaccine development.

20 Jan 2022

Evaporators assist academic drug discovery

BioChromato Inc reports how the renowned Chemistry Research Laboratories (CRL) at Oxford University (UK) are using several Smart Evaporator C1 units to support their drug discovery activities in therapeutic areas including oncology and regenerative medicine.

From BioChromato Inc. 19 Jan 2022

Macrodomains represent a unique target for pathogens with pandemic potential

In a new study published in the journal Pathogens, researchers have summarized the role of the macrodomain in viral replication and virulence and further reviewed the development of macrodomain inhibitors as antiviral agents.

18 Jan 2022

MD Anderson and Eisbach Bio collaborate to develop precision oncology drugs

The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.

18 Jan 2022

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

PhoreMost Ltd today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park.

From PhoreMost 18 Jan 2022

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company.

From Malvern Panalytical 13 Jan 2022